Altimmune director David Drutz will not stand for re-election at 2024 annual meeting

Altimmune, Inc.

David J. Drutz, M.D. notified the Board that he will not stand for re-election at the 2024 Annual Meeting of Shareholders.
Drutz will continue as a director until the date of the Annual Meeting; his decision is not due to any disagreement with the company.
The Board thanked Dr. Drutz for his service; no replacement has been announced as he will not stand for re-election.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David J. Drutz

Director

ALT · Altimmune, Inc.

Filed: August 15, 2024, 7:59 PM ET

On August 13, 2024, David J. Drutz, M.D. notified the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) that he has decided not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Drutz departed as Director at Altimmune, Inc..

Action: decided not to stand for re-election
Role: Director

Exact text from the filing

On August 13, 2024, David J. Drutz, M.D. notified the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) that he has decided not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.